Immunprophylaxe der Hepatitis B

Literatur

• 1 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut/Stand Juli 2002.  Epidem Bull. 2002;  28 227-242 (IV)
• 2 Virushepatitis B und C bis zum Jahr 2001.  Epidem Bull. 2002;  44 369-373 (IV)
• 3 Seaworth B, Drucker J, Starling J. et al . Hepatitis B vaccines in patients with chronic renal failure before dialysis.  J Infect Dis. 1988;  157 332-337 (III)
• 4 Thierfelder W, Meisel H, Schreier E. et al . Die Prävalenz von Antikörpern gegen Hepatitis-A-, Hepatitis-B- und Hepatitis-C-Viren in der deutschen Bevölkerung.  Gesundheitswesen. 1999;  61 (Sonderheft 2) S110-S114 (Ib)
• 5 Jilg W, Hottenträger B, Weinberger K. et al . Prevalence of markers for hepatitis B in the adult German population.  J Med Virol. 2001;  63 96-102 (Ib)
• 6 Coates T, Wilson R, Patrick G. et al . Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines.  Clin Ther. 2001;  23 392-403 (Ia)
• 7 Hadler S C, Francis D P, Maynard J E. et al . Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.  N Engl J Med. 1986;  315 209-214 (Ib)
• 8 Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine.  Infection. 1989;  17 70-76 (IIa)
• 9 West D J, Calandra G. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination.  Vaccine. 1996;  14 1019-1027 (III)
• 10 Wainwright R B, Bulkow L R, Parkinson A J. et al . Protection provided by hepatitis B vaccine in a Yupik escimo population - results of a 10-year study.  J Infect Dis. 1997;  175 674-677 (IIa)
• 11 Anonymous . Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.  Lancet. 2000;  355 561-565 (IV)
• 12 Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory.  Vaccine. 2000;  19 877-885 (III)
• 13 Wismans P J, van Hattum J, Mudde G C. et al . Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response.  J Hepatol. 1989;  8 236-240 (IIa)
• 14 Resti M, Azzari C, Manelli F. et al . Ten-year follow-up study of neonatal hepatitis B immunization: are booster injections indicated?.  Vaccine. 1997;  12/13 1338-1340 (IIb)
• 15 Da Villa G, Pellicia M G, Peluso F. et al . Anti-HBs responses in children vacinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine.  Res Virol. 1997;  148 109-114 (IIb)
• 16 Watson B, West D J, Chilkatowsky A. et al . Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine.  Vaccine. 2001;  19 3164-3168 (IIb)
• 17 Liao S S, Li R C, Li H. et al . Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children.  Vaccine. 1999;  17 2661-2666 (IIb)
• 18 Whittle H, Jaffar S, Wansbrough M. et al . Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children.  BMJ. 2002;  325 569-574 (IIa)
• 19 Wismans P, van Hattum J, Stelling T. et al . Effect of supplementary vaccination in healthy non-responders to hepatitis B vaccination.  Hepato-gastroenterol. 1988;  35 78-79 (IIb)
• 20 Jilg W, Schmidt M, Deinhardt F. Impfversager nach Hepatitis B-Impfung: Effekt zusätzlicher Impfungen.  Dtsch Med Wschr. 1990;  115 1545-1548 (IIb)
• 21 Clemens R, Sänger R, Kruppenbacher J. et al . Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - results of a postmarketing surveillance.  Vaccine. 1997;  15 349-352 (IIb)
• 22 Hasselhorn H M, Kralj N, Hofmann F. et al . [Non- and low-response after preventive hepatitis B vaccination].  Gesundheitswesen. 1997;  59 321-328 (III)
• 23 Rendi-Wagner P, Wiedermann G, Stemberger H. et al . New vaccination strategies for low- and non-responders to hepatitis B vaccine.  Wien Klin Wochenschr. 2002;  114 175-180 (III)
• 24 Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise.  Scand J Infect Dis. 1999;  31 197-200 (IIb)
• 25 Carlsson T, Struve J, Sonnerborg A. et al . The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.  Scand J Infect Dis. 1999;  31 93-95 (IIa)
• 26 Henderson E A, Louie T J, Ramotar K. et al . Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers.  Infect Control Hosp Epidemiol. 2000;  21 264-2649 (Ib)
• 27 Rahman F, Dahmen A, Herzog-Hauff S. et al . Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen.  Hepatology. 2000;  31 521-527 (IIb)
• 28 Anonymous . Immunisation against hepatitis B.  Lancet. 1988;  i 875-876 (IV)
• 29 Bruguera M, Rodicio J L, Alcazar J M. et al . Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients.  Vaccine. 1990;  Suppl S47-S49 (IIa)
• 30 Marangi A L, Giordano R, Montanaro A. et al . Hepatitis B virus infection in chronic uremia: long-term follow-up of a two-step integrated protocol of vaccination.  Am J Kidney Dis. 1994;  23 537-542 (IIb)
• 31 Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling.  Nephron. 1996;  73 417-420 (IIb)
• 32 Rosman A S, Basu P, Galvin K. et al . Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial.  Am J Med. 1997;  103 217-222 (Ib)
• 33 Mettang T, Schenk U, Thomas S. et al . Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study.  Nephron. 1996;  72 192-196 (III)
• 34 Propst T, Propst A, Lhotta K. et al . Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination.  Am J Kidney Dis. 1998;  32 1041-1045 (III)
• 35 Charest A F, McDougall J, Goldstein M B. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients.  Am J Kidney Dis. 2000;  36 976-982 (Ib)
• 36 Kapoor D, Aggarwal S R, Singh N P. et al . Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients.  J Viral Hepat. 1999;  6 405-409 (Ib)
• 37 Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients.  Am J Nephrol. 2000;  20 53-56 (Ib)
• 38 Evans T G, Schiff M, Graves B. et al . The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.  Clin Nephrol. 2000;  54 138-142 (Ib)
• 39 Looney R J, Hasan M S, Coffin D. et al . Hepatitis B immunization of healthy elderly adults: relationship between naive CD4 + T cells and primary immune response and evaluation of GM-CSF as an adjuvant.  J Clin Immunol. 2001;  21 30-36 (Ib)
• 40 André F, Zuckerman A J. Review: Protective efficacy of hepatitis B vaccines in neonates.  J Med Virol. 1994;  44 144-151 (III)
• 41 Mitsui T, Iwano K, Suzuki S. et al . Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls.  Hepatology. 1989;  10 324-327 (III)

Diagnostik und Therapie der chronischen Hepatitis B bzw. B/D

Liste der Teilnehmer

Definition und Diagnostik der akuten und chronischen Hepatitis B und B/D M. Roggendorf, Essen (Vorsitz) G. Gerken, Essen K. Grüngreiff, Magdeburg R. Müller, Siegburg J. Rasenack, Freiburg P. Schirrmacher, Köln H. Will, Hamburg C. Wittekind, Leipzig

Indikationsstellung zur Therapie der chronischen Hepatitis B und B/D C. Niederau, Oberhausen (Vorsitz) W. O. Böcher, Mainz P. R. Galle, Mainz T. Hütteroth, Lübeck S. Matern, Aachen J. Pausch, Kassel J. Petersen, Hamburg W. Stremmel, Heidelberg C. Trautwein, Hannover

Standardtherapie der chronischen Hepatitis B und B/D M. P. Manns, Hannover (Vorsitz) W. H. Caselmann, Bonn T. Goeser, Köln B. Küppers, Mannheim W. E. Schmidt, Bochum K. H. Wiedmann, Regensburg R. Zachoval, München

Vorgehen in Problemsituationen H. E. Blum, Freiburg (Vorsitz) W. Arnold, Bremen T. Berg, Berlin J. Encke, Heidelberg G. Kleber, Aalen R. Somasundaram, Berlin H. L. Tillmann, Leipzig U. Treichel, Essen F. von Weizsäcker, Freiburg

Immunprophylaxe der Hepatitis B und Reinfektionspropylaxe bei LTx W. Jilg, Regensburg (Vorsitz) T. Heintges, Düsseldorf B. Kallinowski, Heidelberg D. Moradpour, Freiburg C. Rink, Aue T. Sauerbruch, Bonn K. Stark, Berlin